CD80 and neoplasm: These observations have led several groups to generate novel therapeutics that provide CD28 costimulation either non-specifically, as with WT CD80 ECD-Fc46, or specifically via a tumor antigen (TA)/CD28 bispecific antibody47 or TA/CD3/CD28 trispecific antibody48.